

Oral Anti Diabetes Drugs Market - 2022

<https://marketpublishers.com/r/O4EAC16B8088EN.html>

Date: November 2025

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: O4EAC16B8088EN

Abstracts

The Oral Anti Diabetes Drugs Market was valued at USD 44.3 billion in 2022 and is anticipated to reach by , at a CAGR of 0.08 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Oral Anti Diabetes Drugs Market.

This report delivers a comprehensive overview of the Oral Anti Diabetes Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Anti Diabetes Drugs Market. The Oral Anti Diabetes Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Oral Anti Diabetes Drugs Market Scope:

By Drug Class

Biguanides

Alpha-glucosidase inhibitors

Dopamine -D2 Receptor Agonist

Sodium-glucose Cotransport -2 (SGLT-2) inhibitor

Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

Sulfonylureas

Meglitinides

By Dosage Type

Liquid

Capsule

Tablet

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Glenmark Pharma

Abbott

Biocon

Sanofi

Sunpharma

Novartis

Novo Nordisk

Merck

GlaxoSmithKline

Bristol-Myers Squibb

Major Highlights

This report delivers a comprehensive overview of the Oral Anti Diabetes Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oral Anti Diabetes Drugs Market. The Oral Anti Diabetes Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Drug Class
- 3.2. Snippet by Dosage Type
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing prevalence of diabetes
 - 4.1.2. Restraints
 - 4.1.2.1. Side effects associated with diabetic drugs
 - 4.1.3. Opportunity
 - 4.1.3.1. Technological advancements
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19
 - 6.1.2. Scenario During COVID-19

- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. ARTIFICIAL INTELLIGENCE ANALYSIS

9. BY DRUG CLASS

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 9.1.2. Market Attractiveness Index, By Drug Class
- 9.2. Biguanides*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 9.2.2.1. Metformin
- 9.3. Alpha-glucosidase inhibitors
- 9.4. Dopamine -D2 Receptor Agonist
 - 9.4.1. Bromocriptin (Cycloset)
- 9.5. Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
 - 9.5.1. Invokana (Canagliflozin)
 - 9.5.2. Jardiance (Empagliflozin)
 - 9.5.3. Farxiga/Forxiga (Dapagliflozin)
 - 9.5.4. Suglat (Ipragliflozin)
- 9.6. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
 - 9.6.1. Januvia (Sitagliptin)
 - 9.6.2. Onglyza (Saxagliptin)
 - 9.6.3. Tradjenta (Linagliptin)
 - 9.6.4. Vipidia/Nesina (Alogliptin)
 - 9.6.5. Galvus (Vildagliptin)
- 9.7. Sulfonylureas
- 9.8. Meglitinides

10. BY DOSAGE TYPE

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type

10.1.2. Market Attractiveness Index, By Dosage Type

10.2. Liquid*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Capsule

10.4. Tablet

11. BY DISTRIBUTION CHANNEL

11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.2. Market Attractiveness Index, By Distribution Channel

11.3. Hospital Pharmacies*

11.3.1. Introduction

11.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

11.4. Retail Pharmacies

11.5. Online Pharmacies

12. BY REGION

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

12.1.2. Market Attractiveness Index, By Region

12.2. North America

12.2.1. Introduction

12.2.2. Key Region-Specific Dynamics

12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type

12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.2.6.1. The U.S.

12.2.6.2. Canada

12.2.6.3. Mexico

12.3. Europe

12.3.1. Introduction

12.3.2. Key Region-Specific Dynamics

12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type

- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 12.3.6.1. Germany
 - 12.3.6.2. The U.K.
 - 12.3.6.3. France
 - 12.3.6.4. Italy
 - 12.3.6.5. Spain
 - 12.3.6.6. Rest of Europe
- 12.4. South America
 - 12.4.1. Introduction
 - 12.4.2. Key Region-Specific Dynamics
 - 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
 - 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 12.4.6.1. Brazil
 - 12.4.6.2. Argentina
 - 12.4.6.3. Rest of South America
- 12.5. Asia-Pacific
 - 12.5.1. Introduction
 - 12.5.2. Key Region-Specific Dynamics
 - 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
 - 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 12.5.6.1. China
 - 12.5.6.2. India
 - 12.5.6.3. Japan
 - 12.5.6.4. Australia
 - 12.5.6.5. Rest of Asia-Pacific
- 12.6. Middle East and Africa
 - 12.6.1. Introduction
 - 12.6.2. Key Region-Specific Dynamics
 - 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
 - 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. COMPETITIVE LANDSCAPE

- 13.1. Competitive Scenario
- 13.2. Product Benchmarking
- 13.3. Company Share Analysis
- 13.4. Key Developments and Strategies

14. COMPANY PROFILES

- 14.1. Glenmark Pharma*
 - 14.1.1. Company Overview
 - 14.1.2. Product Portfolio and Description
 - 14.1.3. Financial Overview
 - 14.1.4. Key Developments
- 14.2. Abbott
- 14.3. Biocon
- 14.4. Sanofi
- 14.5. Sunpharma
- 14.6. Novartis
- 14.7. Novo Nordisk
- 14.8. Merck
- 14.9. GlaxoSmithKline
- 14.10. Bristol-Myers Squibb (*LIST NOT EXHAUSTIVE)

15. APPENDIX

- 15.1. About Us and Services
- 15.2. Contact Us

I would like to order

Product name: Oral Anti Diabetes Drugs Market - 2022

Product link: <https://marketpublishers.com/r/O4EAC16B8088EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O4EAC16B8088EN.html>